CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
Drug
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...
YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam
China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...
Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial
Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has...